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We hypothesized that the influence of cyanotic disease on postoperative blood loss is closely related to age in
children undergoing cardiac surgery. Here, we demonstrate that the presence of a cyanotic disease is associated
with increased postoperative blood loss in children aged 1 to 6 months. Children with cyanotic disease and aged <
1 month who received fresh frozen plasma during cardiopulmonary bypass had less postoperative blood loss and
higher maximal clot firmness on FIBTEM than cyanotic children from all other groups. Additional studies are needed
to define optimal pathophysiology-based management in children undergoing cardiac surgery.
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Children who undergo cardiac surgery develop postoper-
ative coagulopathy due to hemodilution and surgical and
patient-related factors [1,2]. Age and the presence of
cyanotic disease are well recognized as predisposing fac-
tors for postoperative coagulopathy [3,4]. The effects of
these two factors on ROTEM® have been investigated in
different studies [5,6], but the interaction between these
factors and the clinical manifestation of postoperative
bleeding remains to be defined. We hypothesized that
the influence of cyanotic disease on postoperative blood
loss is closely related to age in children undergoing
cardiac surgery.Methods
After approval by the local ethic committee (QFCUH
Ethic Board), we retrospectively reviewed data from our
departmental database for all children scheduled for elect-
ive cardiac surgery with cardiopulmonary bypass (CPB).
The need for informed consent was waived due to the
retrospective nature of the analysis. The anesthetic, CPB,
and surgical techniques are standardized in our depart-
ment. Tranexamic acid was systematically administered
using the same dosing scheme. In terms of anticoagulation,
unfractionated heparin (UFH, 4 mg/kg) was administered* Correspondence: davidfaraoni@icloud.com
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article, unless otherwise stated.before aortic cannulation. The activated clotting time
(ACT) (ACTII monitor, Medtronic BV, Kerkrade, the
Netherlands) was used to guide additional UFH administra-
tion, maintaining a target ACT > 480 sec. At the end of
CPB, protamine was administered to antagonize heparin
activity. Adequate reversal was controlled using the ACTII
monitor to comparing the ACT measured in the cartridge
with and without heparinase (Medtronic BV, Kerkrade, the
Netherlands).
In children older than 1 month of age, 6% hydroxyethyl
starch (HES 130/0.4, Voluven®, Fresenius-Kabi Gmbh, Bad
Homburg, Germany) was systematically used for CPB
priming. In children < 1 month old, fresh frozen plasma
(FFP) replaced the colloid solution. The transfusion algo-
rithm was standardized as described previously [7]. Ten mi-
nutes after protamine administration, blood samples were
drawn to measure platelet count, fibrinogen plasma con-
centration (Claus method), and parameters determined by
the EXTEM and FIBTEM tests on ROTEM® (ROTEM®,
TEM® International GmbH, Munich, Germany).Statistical analysis
Children were characterized into five groups according to
age (< 1 month, 1-6 months, 6-12 months, 1-3 years, >
3 years). In each group, children with cyanotic and non-
cyanotic disease were differentiated. Continuous variables
were tested for normality using the Kolmogorov-Smirnov
test. Data are presented as medians and interquartile
ranges (25th percentile to 75th percentile). CategoricalBioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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loss was measured in the 6th postoperative hour and
expressed as a percentage of the child’s estimated blood
volume (EBV). The EBV and coagulation parameters ob-
tained after heparin antagonization were analyzed using a
two-way ANOVA analysis of variance testing for a differ-
ence between age groups, a difference between cyanotic
and non-cyanotic disease, and for the interaction between
age and cyanotic disease. If significant, Bonferroni’s mul-
tiple comparison test was performed.
Statistical analyses were performed using Prism 6 for
Mac OS (version 6.0a; GraphPad Software Inc., San Diego,
California, USA, www.graphpad.com). A p-value < 0.05 was
considered significant.
Findings
Data was obtained from 182 patients (Table 1). Postopera-
tive blood loss was significantly influenced by age (p =
0.003) and the presence of a cyanotic disease (p = 0.01).
We also identified a significant interaction between these
two factors (p = 0.03).
Postoperative bleeding was significantly higher in the
cyanotic population compared to the non-cyanotic popu-
lation, but only in children aged 1 to 6 months. In the
non-cyanotic population, postoperative blood loss was not
influenced by age (Figure 1). Regarding FFP and platelet
transfusion, no difference was observed between the cyan-
otic and non-cyanotic populations in the different age
groups (Table 2).
Fibrinogen levels were significantly influenced by age
(p < 0.001) but not by the presence of cyanotic disease
(p = 0.3). Interestingly, baseline fibrinogen levels were sig-
nificantly different from post-CPB levels in all age groups
(p < 0.001) except in children < 1 month of age (Figure 2A).
In contrast, platelet count was not influenced by age (p =
0.7), but it was influenced by the presence of cyanotic dis-
ease (p = 0.03; Figure 2B). Similar to fibrinogen, baseline
and post-CPB platelet counts were significantly differentTable 1 Demographic characteristics of the population
Age Cyano. N Age (mo.) Mal
< 1 mo. 1 8 0.3 (0.1 to 0.3) 6
0 21 0.3 (0.2 to 0.7) 12
1 to 6 mo. 1 21 3.8 (3.0 to 5.0) 12
0 24 2.4 (1.7 to 3.7) 10
6 to 12 mo. 1 10 7.0 (6.6 to 8.2) 6
0 15 9.0 (8.0 to 9.5) 8
1 to 3 yr. 1 13 15.7 (13.2 to 18.9) 9
0 25 18.6 (15.0 to 26.8) 12
> 3 yr. 1 12 46.9 (38.0 to 67.3) 8
0 33 73.0 (47.4 to 120.0) 17
Data are expressed as median and interquartile range (25th percentile to 75th perc(p < 0.001). Maximal clot firmness (MCF) obtained on
EXTEM (p < 0.001) or FIBTEM (p < 0.001) were the only
ROTEM® parameters influenced by age. The MCF obtained
on FIBTEM was significantly higher in the presence of
cyanotic or non-cyanotic disease in children aged < 1 month
compared to all other age groups (p < 0.001 for all compari-
sons). The same difference in MCF was observed with
EXTEM in children with cyanotic disease (p < 0.01 for all
comparisons) but not in children with non-cyanotic disease
(p > 0.05 for all comparisons). Finally, ROTEM® parameters
were not significantly different between cyanotic and non-
cyanotic children (Figure 2C and 2D).
Discussion
Based on our preliminary descriptive analyses, postopera-
tive blood loss was significantly influenced by age in the
cyanotic, but not the non-cyanotic, population. The
addition of FFP during CPB in children < 1 month of age
increased the MCF on FIBTEM and EXTEM in the pres-
ence of cyanotic disease. The addition of FFP to CPB in
children < 1 month of age also decreased postoperative
blood loss in children with cyanotic disease, but the evi-
dence seems to be weak in the non-cyanotic population.
Bleeding disorders and abnormal hemostasis in children
with cyanotic disease are well known [8]. Coagulation de-
fects, such as thrombocytopenia, and factor deficiencies,
including low fibrinogen levels and impaired fibrinogen
polymerization, have also been described [9]. In a recent
study, Jensen et al. reported that children with cyanotic
disease are in a hypocoagulable state related primarily to
impaired fibrinogen function, whereas thrombocytopenia,
if present, is not associated with severe platelet dysfunc-
tion [10]. On the other hand, data regarding post-CPB
platelet dysfunction are sparse [11,12]. Using a point-of-
care assessment of platelet aggregation in children under-
going cardiac surgery, Hofer et al. recently reported that
cyanotic patients exhibit better platelet aggregation than
non-cyanotic patients despite increased bleeding tendency,e (%) RACHS Height (cm) Weight (kg)
(75) 3 (3 to 4) 50 (46 to 51) 3.3 (2.9 to 4.0)
(57) 4 (3 to 4) 48 (46 to 50) 2.9 (2.7 to 3.7)
(57) 3 (2 to 4) 57 (55 to 60) 4.4 (3.7 to 6.0)
(42) 2 (2 to 3) 55 (51 to 58) 4.4 (3.6 to 5.6)
(60) 2 (2 to 3) 67 (64 to 70) 6.6 (5.9 to 8.0)
(53) 2 (2 to 3) 68 (65 to 71) 7.0 (5.4 to 7.5)
(69) 2 (2 to 3) 76 (71 to 85) 9.9 (7.6 to 12.1)
(48) 2 (2 to 3) 78 (69 to 87) 9.8 (6.6 to 11.2)
(67) 3 (2 to 3) 100 (92 to 104) 14.1 (13.3 to 15.9)
(52) 3 (2 to 3) 113 (104 to 134) 21.0 (15.6 to 28.7)
entile). Cyano, cyanogen; RACHS, Risk Adjustment for Congenital Heart Surgery.
Figure 1 Blood loss based on age and the presence of cyanotic disease. *p < 0.005 comparing < 1 month and 1-6 months with cyanotic
disease (mean difference between groups 7.9% estimated blood volume (EBV), 95% CI 1.4 to 14); ** p < 0.05 comparing 1-6 months and 6-12 months
with cyanotic disease (mean difference between groups -6.1% EBV, 95% CI -12 to -0.15); *** p < 0.05 comparing 1-6 months and 1-3 years with cyanotic
disease (mean difference between groups -5.6% EBV, 95% CI -11 to -0.12); **** p < 0.005 comparing 1-6 months and > 3 years with cyanotic disease
(mean difference between groups -6.9% EBV, 95% CI -13 to -1.3).
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gen dysfunction in children with cyanotic disease [11].
However, the relationship between platelet function and
perioperative blood loss has only been studied in a pre-
liminary study; Ranucci et al. observed that the use of
platelet function assays is not supported in the pediatric
cardiac population [12]. In addition, no study has assessed
platelet and fibrinogen function simultaneously in children
undergoing cardiac surgery.
In our population, we observed that age influences post-
operative blood loss only in children with cyanotic disease
until the age of 6 months, but no difference was found be-
tween age groups in the non-cyanotic population. Further
well-designed prospective studies are needed to better
understand the pathophysiological mechanisms, but weTable 2 Transfusion data
Age group Cyano. N Expo. to RBC (%) RBC in CPB
< 1 mo. 1 8 6 (75) 4 (50)
0 21 19 (90) 18 (86)
1 to 6 mo. 1 21 15 (71) 8 (38)
0 24 19 (79) 21 (87)
6 to 12 mo. 1 10 2 (20) 1 (10)
0 15 11 (73) 5 (33)
1 to 3 yr. 1 13 4 (31) 2 (15)
0 25 13 (52) 4 (16)
> 3 yr. 1 12 0 (0) 0 (0)
0 33 1 (3) 1 (3)
Data are expressed number and percentage. Cyano, cyanogen; Expo, exposition; RBC, redhypothesize that the immature coagulation system, es-
pecially fibrinogen function, could be more impaired in
children < 6 months of age in the presence of cyanotic
disease. After 6 months of age, the potential difference
in hemostatic physiology between cyanotic and non-
cyanotic diseases is no longer associated with clinically
relevant differences.
We also observed that the addition of FFP significantly
decreased postoperative blood loss in children aged <
1 month compared to those aged 1 to 6 months. The de-
crease in postoperative blood loss seems to be particularly
relevant in children with cyanotic disease. From a patho-
physiological point-of-view, the effect of FFP on blood loss
could be explained by the supplementation of clotting fac-
tors, especially fibrinogen. This conclusion is supported by(%) Expo. to FFP (%) FFP in CPB (%) Expo. to PLT (%)
2 (25) 8 (100) 0 (0)
12 (57) 21 (100) 5 (24)
2 (9) 2 (9) 1 (5)
1 (4) 0 (0) 1 (4)
0 (0) 0 (0) 0 (0)
0 (0) 1 (7) 0 (0)
1 (8) 1 (8) 0 (0)
0 (0) 1 (4) 0 (0)
0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0)
blood cell; FFP, fresh frozen plasma; PLT, platelets; CPB, cardiopulmonary bypass.
Figure 2 Coagulation parameters based on age and the presence of cyanotic disease. (A) Fibrinogen levels measured using the Clauss
method at baseline and after cardiopulmonary bypass (CPB) (p < 0.001). (B) Platelet count at baseline and after CPB (p < 0.001). (C) Maximal clot
firmness obtained on FIBTEM after CPB. (D) Maximal clot firmness obtained on EXTEM after CPB. ***p < 0.001 comparing < 1 month and all other
groups with cyanotic and non-cyanotic diseases, #p < 0.01 comparing < 1 month and all other groups with cyanotic diseases. Blue, cyanotic
patients; red, non-cyanotic patients; clear symbols represent baseline tests; and full symbols represent post-CPB tests.
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creased in children aged < 1 month compared to other age
groups. In addition, we observed that hemodilution ob-
tained during CPB significantly decreased the platelet count
in all children, whereas the fibrinogen level significantly de-
creases in children aged > 1 month. This observation could
support our hypothesis that FFP helped maintain the fi-
brinogen level when used in children aged < 1 month. If the
fibrinogen level needs to be maintained, cryoprecipitate or
fibrinogen concentrates could also be considered and could
results in a lower degree of hemodilution [13].
A recent study reported that fibrinogen concentrate
should be used as a first line therapy in bleeding patientsafter CPB [14]. If no data exist in the pediatric population,
further prospective trials can be performed to assess the
efficacy of fibrinogen concentrates compared to FFP in
children undergoing cardiac surgery. This concentrate-
based approach could decrease hemodilution and decrease
the need for transfusion. The results of these analyses
should be interpreted with caution due to the risk of bias,
but our hypothesis can be assessed in a large, prospective
trial.
Conclusion
In conclusion, our understanding of the pathophysio-
logical mechanisms leading to increases bleeding risks in
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weak. Further prospective studies are needed to assess the
relationship between postoperative blood loss, hemodilu-
tion, platelet dysfunction, and/or fibrinogen deficiency. A
better understanding of these mechanisms would lead to
better goal-directed management, considering that chil-
dren with cyanotic disease may need to be treated with
different targets than those with non-cyanotic disease.
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